OBJECTIVES : Some drugs recommended for COVID-19 treatment by WHO are used for other diseases, others require clinical trials to confirm their effectiveness. Ministries of Health or other similar authorized institutions allow use of such drugs in strictly controlled clinical trials or under special procedures. Our research aim was to study the state of physical availability and affordability of protocol drugs for treatment of coronavirus disease COVID-19 in Ukraine.

METHODS : Comparative analysis of clinical protocols for treatment of COVID-19 and data from State Registers of Medicines (SRM) of Ukraine.

RESULTS : In Ukraine two special drugs: remdesivir and favipivir are included in clinical protocols (orders of the Ministry of Health № 762 from 02.04 ® № 2583 from 11.11.2020), but unlike model WHO protocol, which includes remdesivir, Ukrainian protocols doesn’t indicate their experimental use or experimental treatment.

Drugs, recommended by Ukraine protocols, according to SRM: tocilizumab is registered under 1 tradename in 2 technological forms: concentrate for infusion solution and solution for injection. Lopinavir is registered only in combination with ritonavir under 2 tradenames in 2 technological forms: tablets in 2 dosages and solution for oral administration. In addition, ritonavir is registered under 1 tradename alone and under another tradename in a triple combination.

In general, INN Azithromycin as a first-line drug for the treatment of pneumonia, as a complication of COVID-19, in SRM of Ukraine appears under 77 trade names (including dosages and technological forms); 62 of them are included in National List. Dexamethasone, recommended as an adjunct to combination therapy, is listed under 27 items in SRM. Enoxaparin as low molecularweight heparin is listed in SRM under 5 items.

CONCLUSIONS : Analysis of Ukraine SRM showed that new experimental antiviral drugs remdesivir and favipivir included in clinical protocol for COVID-19 treatment in Ukraine are unregistered and generally absent.